Cor Vasa 2017, 59(1):e29-e34 | DOI: 10.1016/j.crvasa.2017.01.022

Special considerations on TAVI implanted in bicuspid aortic valves. Experience of Institute of Cardiology in Warsaw, Poland

Mikołaj Kosek^a,*, Jan Jastrzębski^a, Krzysztof Kuśmierski^b, Maciej Dąbrowski^a, Piotr Szymański^c, Ilona Michałowska^d, Tomasz Hryniewiecki^c, Marcin Demkow^e, Janina Stępińska^f, Piotr Michałek^g, Zbigniew Chmielak^a, Adam Witkowski^a

^a Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland

^b Department of Cardiosurgery and Transplantology, Institute of Cardiology, Warsaw, Poland

^c Department of Acquired Cardiac Defects, Institute of Cardiology, Warsaw, Poland

^d Department of Radiology, Institute of Cardiology, Warsaw, Poland

^e Department of Coronary and Structural Heart Diseases, Institute of Cardiology, Warsaw, Poland

^f Department of Cardiac Intensive Therapy, Institute of Cardiology, Warsaw, Poland

^g Emergency Ward, Institute of Cardiology, Institute of Cardiology, Warsaw, Poland

Since the advent of transcatheter aortic valve implantation (TAVI), bicuspid aortic valves (BAVs) have been considered relative contraindication for this procedure. Patients with BAVs were excluded from the majority of large clinical TAVI trials. However, the development of the implantation technique and further studies have proven this method feasible and safe also in BAVs. Nowadays some clinicians claim that BAV should no longer be a contraindication. Nevertheless special aspects of the unique anatomy need to be taken into consideration when qualifying patients for this procedure. In our center since 2010 a total number of 28 patients with bicuspid aortic valve stenosis underwent TAVI.

Keywords: Aortic valve stenosis; BAV stenosis; Bicuspid aortic valve; TAVI; Transcatheter heart valve

Received: November 30, 2016; Accepted: January 12, 2017; Published: February 1, 2017  Show citation